ILIAS Biologics Inc. is successfully wrapping up the Phase 1 clinicial trial for our ILB-202, marking a global first in the systemic administration of engineered exosomes.

ILIAS Biologics Inc. is successfully wrapping up the Phase 1 clinicial trial for our ILB-202, marking a global first in the systemic administration of engineered exosomes. This is not merely about ILB-202’s safety validation; it represents a significant human proof-of-concept for our innovative exosome platforms. Additionally, by analyzing PD biomarkers from human blood samples, we will obtain evidence of potential efficacy. News Link PREV LIST NEXT Ilias Company name ILIAS Biologics Inc. CEO Chulhee Choi Corporate registration number 161-86-00309 ADDRESS 40-20 Techno 6-ro, Yuseong-gu, Daejeon, 34014, Republic of Korea TEL 042-863-4450 FAX 042-863-4499 ⓒ 2021 ILIAS Biologics Inc. ALL RIGHTS RESERVED.

The release as fetched from its publisher. iliasbio.com ↗